Status
Conditions
Treatments
About
The purpose of the study is to assess the efficacy, safety and the clinical benefit of the SiREX stent for the treatment of disabling pulsatile tinnitus due to stenosis of lateral sinus.
The study will enrol patients suffering from pulsatile tinnitus related to a lateral sinus stenosis lasting more than three months, and who want to be treated with lateral sinus stenting
Full description
As there is currently no specifically developed and approved stent on the market for the treatment of symptomatic sinus stenosis, stenting has so far been performed with stents intended for carotid stenosis or peripheral treatment, which leads to considerable limitations. Because of stiff delivery systems (6F or bigger) progression inside the venous sinus is sometimes difficult. Furthermore, the length of such devices is often insufficient to cover the entire pathological segment and more than one device needs to be implanted in an overlaying manor (telescoping), which is accompanied with higher complication risks.
The objective of the study is to prove the efficacy and clinical safety of the new dedicated SiREX Stent with optimized technical features (smaller delivery system, longer lengths, reduced radial force), specially developed for the treatment of venous sinus stenosis. Pulsatile tinnitus is expected to disappear immediately after treatment with a stable effect during time.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
• Patient ≥ 18 years old
Exclusion criteria
Non-pulsatile tinnitus or pulsatile tinnitus unrelated to lateral sinus stenosis
Stenosis with gradient < 2 mm Hg in the absence of associated lateral sinus dehiscence
Any contraindication for treatment according to Instructions for Use:
Pregnant or breastfeeding woman
Subject is participating in another clinical study
Patients with a life-threatening event in the last 6 months
Patients with a life expectancy under 12 months
Known, severe comorbidities, which will likely influence carrying out of the follow-up visits (cancer, alcohol/drug abuse or dementia)
Primary purpose
Allocation
Interventional model
Masking
78 participants in 1 patient group
Loading...
Central trial contact
Anna Gold
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal